Menu Search
Equities

Embecta Corp

EMBC:NSQ

Embecta Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)15.71
  • Today's Change0.20 / 1.29%
  • Shares traded1.00
  • 1 Year change-3.56%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform0
Hold3
Sell2
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Embecta Corp have a median target of 17.00, with a high estimate of 18.20 and a low estimate of 13.00. The median estimate represents a 8.21% increase from the last price of 15.71.
High15.8%18.20
Med8.2%17.00
Low-17.3%13.00

Dividends in USD

In 2023, Embecta Corp reported a dividend of 0.60 USD. The 3 analysts covering the company expect dividends of 0.59 USD for the upcoming fiscal year, a decrease of 1.67%.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Aug 09, 2024, Embecta Corp reported 3rd quarter 2024 earnings of 0.74 per share. This result exceeded the 0.46 consensus of the 5 analysts covering the company and exceeded last year's 3rd quarter results by 7.25%.
The next earnings announcement is expected on Nov 19, 2024.
Average growth rate+2.30%
Embecta Corp reported annual 2023 earnings of 2.99 per share on Nov 21, 2023.
Average growth rate-50.74%
More ▼

Revenue history & estimates in USD

Embecta Corp had 3rd quarter 2024 revenues of 272.50m. This bettered the 267.44m consensus of the 4 analysts covering the company. This was 1.16% below the prior year's 3rd quarter results.
Average growth rate-1.16%
Embecta Corp had revenues for the full year 2023 of 1.12bn. This was 0.77% below the prior year's results.
Average growth rate-0.77%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.